Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Announces Financial Results for the Third Quarter 2015
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 4, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced financial results for the third quarter and nine months ended September 30, 2015 .
Toggle Summary Aimmune Therapeutics to Present at the 2015 Credit Suisse Healthcare Conference
— Presentation on November 11, 2015 , at 2:00 p.m. MT — BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the 2015 Credit Suisse
Toggle Summary Aimmune Therapeutics Announces COO Transition
— COO Howard Raff to Retire from Leadership Position to Focus on Future Pipeline Development — — Aimmune Builds Clinical Team with Key Allergist / Immunologist Hires — BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 9, 2015-- Aimmune Therapeutics, Inc.
Toggle Summary Aimmune Therapeutics Receives EMA Decision Agreeing With PIP for AR101 for the Treatment of Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Oct. 7, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it has received the European Medicines Agency (EMA) decision endorsing the company’s pediatric
Toggle Summary Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
— Presentation on September 18, 2015 , at 9:45 a.m. GMT — BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 2, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, today announced that it will present at the Bank of America
Toggle Summary Aimmune Therapeutics Reports Second Quarter 2015 Financial Results
-- IPO Netted $168 Million for Strong Cash Position -- -- Phase 3 Trial Planned for Early 2016 Based on Successful Phase 2 Trial -- BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 31, 2015-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for
Toggle Summary Aimmune Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 11, 2015-- Aimmune Therapeutics, Inc. , today announced the closing of its initial public offering of 11,499,999 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions, which includes the
Toggle Summary Aimmune Therapeutics Announces Pricing of Initial Public Offering
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 5, 2015-- Aimmune Therapeutics, Inc. today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions.
Toggle Summary Aimmune Therapeutics Files Registration Statement for Initial Public Offering
BRISBANE, Calif., July 6, 2015 — Aimmune Therapeutics, Inc., today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price
Toggle Summary Aimmune Therapeutics Receives FDA Breakthrough Therapy Designation for AR101
FDA Breakthrough Therapy Designation for AR101 oral immunotherapy of peanut-allergic children and adolescents follows positive Phase 2 study results BRISBANE, Calif., June 18, 2015 — Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for